Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

• Published in: Headache Vol. 61; no. 9; pp. 1351 - 1363
• Main Authors: Barbanti, Piero, Aurilia, Cinzia, Cevoli, Sabina, Egeo, Gabriella, Fofi, Luisa, Messina, Roberta, Salerno, Antonio, Torelli, Paola, Albanese, Maria, Carnevale, Antonio, Bono, Francesco, D'Amico, Domenico, Filippi, Massimo, Altamura, Claudia, Vernieri, Fabrizio, Colombo, Bruno, Frediani, Fabio, Mercuri, Bruno, D'Onofrio, Florindo, Grazzi, Licia, Aguggia, Marco, Pierangeli, Giulia, Favoni, Valentina, Finocchi, Cinzia, Di Fiore, Paola, Costa, Carmelina Maria, Brunelli, Nicoletta, Fallacara, Adriana, Bertuzzo, Davide, Zucco, Maurizio, Di Clemente, Laura, Trimboli, Michele, Pascarella, Angelo, Manzo, Lucia
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2021
• Subjects: Adult; allodynia; Analgesics; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage; Calcitonin Gene-Related Peptide Receptor Antagonists - adverse effects; Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology; calcitonin gene‐related peptide; Chronic Disease; Clinical trials; erenumab; Failure; Female; Headache; Headaches; Humans; Hyperalgesia - physiopathology; Impact tests; Italy; Longitudinal Studies; long‐term treatment; Male; Males; Middle Aged; Migraine; Migraine Disorders - physiopathology; Migraine Disorders - prevention & control; Monoclonal antibodies; Outcome Assessment, Health Care; Pain perception; Patients; Placebos; Prevention; Safety; Sex; Sex Factors; Italy; long-term treatment; calcitonin gene-related peptide; allodynia; migraine; erenumab; sex

Objective To evaluate the long‐term effectiveness, safety, and tolerability of erenumab in a real‐world migraine population, looking for putative predictors of responsiveness. Background Erenumab proved to be effective, safe, and well tolerated in the prevention of episodic migraine (EM) and chronic...